HK5996A - 2-substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof - Google Patents

2-substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof Download PDF

Info

Publication number
HK5996A
HK5996A HK5996A HK5996A HK5996A HK 5996 A HK5996 A HK 5996A HK 5996 A HK5996 A HK 5996A HK 5996 A HK5996 A HK 5996A HK 5996 A HK5996 A HK 5996A
Authority
HK
Hong Kong
Prior art keywords
dioxolane
hydroxymethyl
trans
cis
isomer
Prior art date
Application number
HK5996A
Other languages
German (de)
English (en)
Inventor
Belleau Bernard
Dixit Dilop
Nguyen-Ba Nghe
Original Assignee
Shire Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22657287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK5996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Canada Inc. filed Critical Shire Canada Inc.
Publication of HK5996A publication Critical patent/HK5996A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Secondary Cells (AREA)
  • Paints Or Removers (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

  1. Procédé pour la fabrication d'une composition pharmaceutique, comprenant le mélange d'un dérivé de 1,3-dioxalane de formule générale (L), d'isomères géométriques et optiques de celui-ci, ou de mélanges de ces isomères : dans laquelle :
    - R₁ est choisi au sein du groupe comprenant l'hydrogène, un groupe acyle comportant 1 à 16 atomes de carbone, les groupes benzoyle et benzoyle substitué en une position quelconque par au moins un atome d'halogène, et par les groupes alkyle C₁-C₃, alcoxy C₁-C₃, nitro et trifluorométhyle; et
    - R₂ est un analogue d'une base nucléoside quelconque, avec un véhicule pharmaceutiquement acceptable.
  2. Procédé selon la revendication 1, dans lequel R₂ est un radical hétérocyclique choisi parmi : dans lequel :
    - R₃ et R₄ sont choisis indépendamment au sein du groupe comprenant l'hydrogène et les groupes alkyle C₁-C₃; et R₅ est choisi parmi le groupe comprenant les groupes alkyle C₁-C₃ et un halogène.
  3. Procédé selon la revendication 1, ou la revendication 2, dans lequel le dérivé de 1,3-dioxalane de formule générale (L) est choisi parmi les composés suivants :
    - le 2-acétoxyméthyl-4-(thymin-1'-yl)-1,3-dioxalane,
    - le 2-hydroxyméthyl-4-(thymin-1'-yl)-1,3-dioxalane,
    - le 2-benzoyloxyméthyl-4-(cytosin-1'-yl)-1,3-dioxalane,
    - le trans 2-hydroxyméthyl-4-(cytosin-1'-yl)-1,3-dioxalane,
    - le 2-benzoyloxyméthyl-4-(adénin-9'-yl)-1,3-dioxalane,
    - le 2-hydroxyméthyl-4-(adénin-9'-yl)-1,3-dioxalane.
    - le 2-benzoyloxylméthyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxalane,
    - le 2-hydroxyméthyl-4-(2'-amino-6'-chloro-purin-9'-yl)-1,3-dioxalane,
    - le 2-hydroxyméthyl-4-(2'-amino-purin-9'-yl)-1,3-dioxalane.
    - le 2-hydroxyméthyl-4-(2',6'-diamino-purin-9'-yl)-1,3-dioxalane, et
    - le 2-hydroxyméthyl-4-(guanin-9'-yl)-1,3-dioxalane.
HK5996A 1988-04-11 1996-01-11 2-substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof HK5996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17961588A 1988-04-11 1988-04-11

Publications (1)

Publication Number Publication Date
HK5996A true HK5996A (en) 1996-01-19

Family

ID=22657287

Family Applications (1)

Application Number Title Priority Date Filing Date
HK5996A HK5996A (en) 1988-04-11 1996-01-11 2-substituted-4-substituted-1,3-dioxolanes, synthesis and use thereof

Country Status (16)

Country Link
EP (1) EP0337713B1 (fr)
JP (1) JP3085675B2 (fr)
KR (1) KR0137023B1 (fr)
AT (1) ATE129247T1 (fr)
AU (1) AU631786B2 (fr)
CA (1) CA1339609C (fr)
DE (1) DE68924549T2 (fr)
DK (1) DK175372B1 (fr)
ES (1) ES2078234T3 (fr)
GR (1) GR3017812T3 (fr)
HK (1) HK5996A (fr)
IE (1) IE71225B1 (fr)
IL (1) IL89921A (fr)
NZ (1) NZ228645A (fr)
OA (1) OA09470A (fr)
ZA (1) ZA892645B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597824A (en) * 1987-11-03 1997-01-28 Abbott Laboratories Analogs of oxetanyl purines and pyrimidines
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
IE904378A1 (en) 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
DK0560794T3 (da) * 1990-11-13 1996-12-23 Iaf Biochem Int Substituerede 1,3-oxathiolaner med antivirale egenskaber
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
RU2235724C2 (ru) * 1992-02-12 2004-09-10 Эмори Юниверсити Способы разделения смеси энантиомеров
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (fr) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides avec activite virale anti-hepatite b
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
AU739240B2 (en) * 1997-03-19 2001-10-04 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
WO1999043691A1 (fr) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
EP1754710A3 (fr) 1998-02-25 2007-12-19 Emory University 2'-Fluoronucleosides
ATE292631T1 (de) 1998-08-12 2005-04-15 Gilead Sciences Inc Verfahren zu herstellung von 1,3-oxathiolane nukleosiden
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
WO2000026225A2 (fr) 1998-11-05 2000-05-11 Centre National De La Recherche Scientifique Nucleosides possedant une activite dirigee contre le virus de l'hepatite b
MXPA01006425A (es) * 1998-12-23 2002-06-04 Iaf Biochem Int Analogos de nucleosido antivirales.
WO2000057861A2 (fr) * 1999-03-29 2000-10-05 Shire Biochem Inc. Techniques de traitement de la leucemie
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
CA2385349A1 (fr) * 1999-09-24 2001-04-05 Francis J. Giles Methode de traitement ou de prevention d'infections virales au moyen d'analogues nucleosidiques
US6566365B1 (en) * 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1600452A3 (fr) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthèse de 2'-déoxy-L-nucléosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2002212015B2 (en) * 2000-10-13 2007-01-25 Shire Canada Inc. Dioxolane analogs for improved inter-cellular delivery
CN102942563A (zh) 2001-03-01 2013-02-27 基利得科学公司 顺-ftc的多晶型物及其它晶型
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
CA2554782C (fr) 2004-02-03 2013-08-13 Emory University Methodes de fabrication de nucleosides de 1,3-dioxolane
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
EP2217229B1 (fr) 2007-10-20 2020-10-14 Athenex, Inc. Compositions pharmaceutiques pour la modulation d'une cascade de kinases et leurs procédés d'utilisation
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
ES8801303A1 (es) * 1985-05-15 1987-12-16 Wellcome Found Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.

Also Published As

Publication number Publication date
KR0137023B1 (ko) 1998-04-25
DK175372B1 (da) 2004-09-13
IE71225B1 (en) 1997-02-12
DK172089D0 (da) 1989-04-10
AU631786B2 (en) 1992-12-10
EP0337713B1 (fr) 1995-10-18
DE68924549D1 (de) 1995-11-23
EP0337713A3 (en) 1990-11-22
KR890016046A (ko) 1989-11-28
CA1339609C (fr) 1997-12-30
OA09470A (en) 1992-11-15
ES2078234T3 (es) 1995-12-16
JPH01316375A (ja) 1989-12-21
GR3017812T3 (en) 1996-01-31
DE68924549T2 (de) 1996-04-04
IL89921A (en) 1993-08-18
EP0337713A2 (fr) 1989-10-18
IL89921A0 (en) 1989-12-15
ZA892645B (en) 1989-12-27
IE891136L (en) 1989-10-11
ATE129247T1 (de) 1995-11-15
NZ228645A (en) 1991-09-25
AU3264489A (en) 1989-10-12
DK172089A (da) 1989-10-12
JP3085675B2 (ja) 2000-09-11

Similar Documents

Publication Publication Date Title
EP0337713B1 (fr) 1,3-Dioxolanes substitués en 2 et 4, leur synthèse et leur utilisation
US5041449A (en) 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5270315A (en) 4-(purinyl bases)-substituted-1,3-dioxlanes
US5486520A (en) 1,3-oxathiolanes useful in the treatment of hepatitis
EP3478692B1 (fr) Dérivés d'oxadiazepinone et leur utilisation pour le traitement des infections hepatites b
EP0560794B1 (fr) 1,3-oxathiolanes substitues ayant des proprietes antivirales
RU2092485C1 (ru) 1,3-оксатиолан, его геометрические и оптические изомеры, смеси этих изомеров, способ их получения и фармацевтическая композиция, проявляющая антивирусную активность
US5736549A (en) Hypoxanthine and guanine compounds
FI90422B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten purinyyli- ja pyrimidinyylisyklobutaanijohdannaisten valmistamiseksi
US6350753B1 (en) 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
EP0480713A1 (fr) Agents antivireux et immunomodulants à base de nucléosides
JPH0680061B2 (ja) 新規なプリン誘導体
US7122693B2 (en) Acetaldehyde acetal compounds, their synthesis, and uses thereof
US7119202B1 (en) Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
HK1005542B (en) 1,3-oxathiolanes useful in the treatment of hepatitis
HK1009270B (en) Substituted-1,3-oxathiolanes with antiviral properties
IE19960758A1 (en) Substituted-1,3-oxathiolanes with antiviral properties
IE83856B1 (en) Substituted-1,3-oxathiolanes with antiviral properties

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20090410